Newspaper Page Text
A SPIRIVA HandiHaler
(tmtmnaim bromide inhalation powder)
Spiriva HandiHaler (tiotropium bromide inhalation powder)
FOR ORAL INHALATION ONLY
Brief Summary of Prescribing Information
INDICATIONS AND USAGE
SPIRIVA HandiHaler (tiotropium bromide inhalation powder) is indicated for the
long-term, once-daisy. maintenance treatment of bronchospasm associated with
chronic obstructive pulmonary disease (COPD). including chronic bronchitis and
emphysema
CONTRAINDICATIONS
SPIRIVA HandiHaler (tiotropium bromide inhalation powder) is contraindicated
in patients with a history of hypersensitivity to atropine or its derivatives, includ
ing ipratropium, or to any component of this product.
WARNINGS
SPIRIVA HanoiHaier (tiotropium bromide inhalation powder) is intended as a
once-daiiy maintenance treatment for COPD and is not indicated for the initial
treatment of acute episodes of bronchospasm. i.e.. rescue therapy Immediate
hypersensitivity reactions, including angioeoema. may occur after administration
of SPIRIVA. If such a reaction occurs, therapy with SPIRIVA should be stopped at
once and alternative treatments should be considered. Inhaled medicines, includ
ing SPIRIVA may cause parade* ca bronchospasm. If this occurs, treatment with
SPIRIVA should be stopped ano other treatments considered.
PRECAUTIONS
General
As an anbchohnergK drug. SPIRIVA (tiotropium bromide inhalation powder)
may potentially worsen symptoms and s’gns associated with narrow-angle
glaucoma, prostatic hyperplasia or bladder-neck obstruction and should be
used with caution in patients with any of these conditions. As a predominantly
renaHy excreted drug, patients with moderate to severe renal impairment (creatinin
clearance of sSO ml/min) treated with SPIRIVA should be monitored closely (see
CLINICAL PHARMACOLOGY. Pharmacokinetics, Special Populations. Renolby
impotred Patterns)
Information for Patients
It is important for patients to understand how to correctly administer SPIRIVA
capsules using the HandiHaler inhalation device (see Patient's Instructions for Use).
SPIRIVA capsules should only be administered via the HandiHaler device and the
HanchHaier device should not be.used for administering other medications. Capsules
should always be stored in sealed blisters. Remove only one capsuie immedi
ately before use. or its effectiveness may be recuced Additional capsules that
are exposed to air (i.e. not intended for immediate use) should be discarded.
Eye pain or discomfort, blurred vision, visual halos or colored images in association
with red eyes from conjunctival congestion and corneal edema may be signs of acute
narrow-angle glaucoma. Should any of these signs and symptoms develop, consult
a physiaan immediatefy. Miotic eye drops alone are not considered to be effective
treatment. Care must be taker not to allow the powder to enter into the eyes as this may
cause tturring of vision and puofi dilation.
SPIRIVA HandiHaler is a once-daiiy maintenance bronchodilator and should not be used
♦or immediate •efcef of breathing problems. Le.. as a rescue medication
Drug Interactions
SPIRIVA has been used concomitantly with other drugs commonly used in COPD
without increases n adverse drug reactions These include sympathomimetic
bronchodnators. methyixanrvnes, and oral ano inhaled steroids. However, the
co-admmistration of SPIRIVA with other anticholinergic-containing drugs (e.g..
pratropium) has not been studied and is therefore not recommended.
Drug/Laboratory Test Interactions
None known
Carcinogenesis, Mutagenesis, Impairment of Fertility
No evidence of tumorgemety was observed in a 104-week inhalation study in
rats at botropium doses up to 0 059 mg/kg/day. in an 83-week inhalation study
-.n female mice at doses up to 0.145 mg <g day. and in a 101-week inhalation
study in male mice at ooses up to 0.002 mg/kg day. These doses correspond to
25. 35, and 0.5 times the Recommended Human Daily Dose (PJ-iDD) or a mg/m 2
oasis, respectively. Tnese dose multiples may be over-estimated due to difficul
ties in measuring deposned Ooses in animal inhalation studies. Tiotropium bromide
Demonstrated no evidence of mutagenicity or dastogenicitv in the following
assays: the bacterial gene mutation assay, the VI9 Chinese hamster cell mutagen
eses assay. We chromosomal aberration assays n human lymphocytes >n vitro and
mouse micronudeus formation in vivo, and the unschedulec DNA synthesis in
primary rat nepatocytes in vrtre assay. In rats, decreases in the number of corpora
tutee arc the percentage of implants were noted at inhalation tiotropium doses of
0.078 mg/kc/day v greater (approximately 35 times the RHDD on a mg/m 2 basis)
No such effect were observed at C. 009 mg/kg/day (approx:matety 4 times than
the RHDD on a mg/m 4 basis). The fertility index, however, was not affected at
inhalation doses up to 1.689 mg/kg/day (approximately 760 times the RHDD on a
mg/m 2 basis). These dose multiples may be over-estimated due to difficulties in
measuring deposttec doses in animal inhalation studies.
Pregnancy
Pregnancy Category C
No evidence of structural alterations was observed ;n rats and rabb’ts at inhalation
tiotropium doses of up to 1.471 and 0.007 mg/kg/day. respectively. These doses
correspond tc approximately 660 and 6 times the recommended human daily dose
(RHDD) on a mg/m* basis However. ;n rats, fetal resorption, litter loss, decreases
■r, t*»e number of bve pups at birth and the mean pup weights, and a delay in pup
sexual maturation were observed at inhalation tiotropium doses of 20.078 mg/kg
(approximately 35 times the RHDD on a mg/m* basis). In rabbits, an increase in post
mplantatior «ss was observed at an inhalation dose of 0.4 mg/kg/day (approxi
mately 360 times the RHDD on a mg/m* basis). Such effects were not observed at
inhalation doses of 0.009 and up to 0.088 mg/kg/day in rats and rabbits, respectively.
These doses correspond to approximately 4 and 80 times the RHDD on a mg/m*
basis, respectively. These dose multiples may be over-estimated due to difficulties in
measunng deposited doses m animal inhalation studies. There are no adequate and
we«-controi«d studies in pregnant women. SPIRIVA should be used during pregnan
cy omy ;f the potential benefit justifies the potential risk to the fetus
Use in Labor and Delivery
The safety anc effectiveness of SPIRIVA has not been studied during labor and delivery.
Nursing Mothers
Conical data from nursing women exposed to tiotropium are not available. Based
on lactatmg rodent stud es, tiotropium is excreted into breast milk. It is not
known whether rotropium is excreted in human milk, but because many drugs
are excreted in human milk and g ; ven these findings in rats, caution should be
exercised if SPIRIVA is administered to a nursing woman
Pediatric Use
SPIRIVA HandiHaler is approved for use in the maintenance treatment of broncho
spasm associated with chronic obstructive pulmonary d ; sease. including chronic
bronchitis and emphysema This d sease does not normally occur in children The
safety and effectiveness SPIRIVA m pediatric patients have not been established.
Geriatric Use
Of the total number of patients who received SPIRIVA in the 1-year clinical
trials 426 were <65 years. 375 were 65-74 years and 105 were *75 years of age
Withm each age subgroup, there were no differences between the proportion of
patients with adverse events in the SPIRIVA and the comparator groups for most
events. Dry mouth increased with age in the SPIRIVA group (differences from
placebo were 9.0%, 17.1%, and 16.2% in the aforementioned age subgroups).
A higher frequency of constipation and urinary tract infections with increasing
age was observed in the SPIRIVA group in the placebo-controlled studies. The
differences from placebo for constipation were 0%. 1.8%. and 7.8% for each of
the age groups. The differences from placebo for urinary tract infections were
-0.6%. 4 6% and 4.5% No overall differences in effectiveness were observed
among these groups Based on available data, no adjustment of SPIRIVA dosage
in geriatric patients is warranted.
ADVERSE REACTIONS
Of the 2.663 patients in the four 1-year and two 6-month controlled clinical trials,
1.308 were treated with SPIRIVA (tiotropium bromide inhalation powder) at the
recommended dose of 18 meg once a day. Patients with narrow angle glaucoma,
or symptomatic prostatic hypertrophy or bladder outlet obstruction were excluded
from these tnals The most commonly reported adverse drug reaction was dry mouth.
Dry mouth was usually mild and often resolved during continued treatment. Other
reactions reported in individual patients and consistent with possible anticholinergic
effects included constipation, increased heart rate, blurred vision, glaucoma, urinary
difficulty, and urinary retention. Four multicenter. 1-year, controlled studies evaluat
ed SPIRIVA in patients with COPD. Table 1 shows all adverse events that occurred
with a frequency of *3% in the SPIRIVA group in the 1-year placebo-controlled trials
where the rates in the SPIRIVA group exceeded placebo by *l%. The frequency of
corresponding events in the ipratropium-controlled trials is included for comparison.
Table 1: Adverse Experience Incidence (% Patients) in One-Year-COPD Clinical Trials
Body System (Event) PtaceboGontrotted Trials IpratropiumGontroMed Trials
SPIRIVA Placebo SPIRIVA Ipratropium
Body as a Whole
Accidents 13 11 5 8
Chest Pain (non-specific) 7 5 5 2
Edema, Dependent 5 4 3 5
Gastrointestinal System Disorders
Abdominal Pain 5 3 6 6
Constipation 4 2 1 1
Dry Mouth 16 3 12 6
Dyspepsia 6 5 1 1
Vomiting 4 2 12
Musculoskeletal System
Myalgia 4 3 4 3
Resistance Mechanism Disorders
Infection 4 3 1 3
Moniliasis 4 2 3 2
Respiratory System (upper) ”
Epistaxis 4 2 1 1
Pharyngitis 9 7 7 3
Rhinitis 6 5 3 2
Sinusitis 11 (i 3 2
Upper Respiratory Trad Infection 41 37 43 35
Skin and Appendage Disorders ~
Rash 4 2 2 2
Urinary System
Urinary Tract Infection 7 5 4 2
Arthritis. coughing, and influenza-like symptoms occurred at a rate of *3% in
the SPIRIVA treatment group, but were <l% in excess of the placebo group.
Other events that occurred in the SPIRIVA group at a frequency of 1-3% Tn the
placebo-controlled trials where the rates exceeded that in the placebo group include:
Body as 0 Whole: allergic reaction. i e g pain; Central and Peripheral Nervous System:
dysphoma. paresthesia: Gastrointestinal System Disorders: gastrointestinal disorder
not otherwise specified (NOS), gastroesophageal reflux, stomatitis (including ulcerative
stomatitis); Metabolic ond Nutritional Disorders: hypercholesterolemia, hyperglyce
mia; Musculoskeletal System Disorders: skeletal pain; Cardiac Events: angina pectoris
(including aggravated angina pectoris); Psychiatric Disorder: depression; Infections:
herpes zoster. Respiratory System Disorder (Upper): laryngitis; Vision Disorder.
cataract In addition, among the adverse events observed in the clinical trials with an
incidence of <l% were atrial fibrillation, supraventricular tachycardia, angioedema.
and urinary retention. In the 1-year trials, the incidence of dry mouth, constipa
tion. and urinary tract infection increased with age (see PRECAUTIONS. Geriatric
Use). Two multicenter. 6-month, controlled studies evaluated SPIRIVA in patients
wuh COPD. The adverse events and the incidence rates were similar to those seen in the
1-year controlled trials. The following adverse reactions have been identified during
worldwide post-approval use of SPIRIVA dizziness, dysphagia, epistaxis. hoarseness,
intestinal obstruction including ileus paralytic, intraocular pressure increased, oral
candidiasis, palpitations, pruritus, tachycardia, throat irntation. and urticaria.
DOSAGE AND ADMINISTRATION
The recommended dosage of SPIRIVA HandiHaler (tiotropium bromide inhalation
powder) is the inhalation of the contents of one SPIRIVA capsule, once-daily. with the
HandiHaler inhalation device (see Patient's Instructions for Use). No dosage adjust
ment is required for geriatric, hepaticaliy-impaired. or renally-impaired patients.
However, patients with moderate to severe renal impairment given SPIRIVA should
be monitored closely (see CLINICAL PHARMACOLOGY, Pharmacokinetics, Special
Populations and PRECAUTIONS). SPIRIVA capsules are for inhalation only and
must not be swallowed.
HOW SUPPLIED
The following packages are available:
carton containing 5 SPIRIVA capsules (1 unit-dose blister card) and
1 HandiHaler inhalation device (NDC 0597-0075-75)
carton containing 30 SPIRIVA capsules (3 unit-dose blister cards) and
1 HandiHaler inhalation device (NDC 0597 0075-41)
carton containing 90 SPIRIVA capsules (9 unit-dose blister cards) and
1 HandiHaler inhalation device (NDC 0597 0075-47)
SV-BS (10-06)
65626/US/1
Rt only
SPUOOO46B
Copyrigtit ©2007. Boennnger Ingelheim Pharmaceuticals. Inc. All rights reserved. (3/07)
®Boehringer
Ingelheim
5V44079
Gardeniffl
m by KATHY
LaLIBERTE
Tending Your
Fall Garden
As cooler weather approaches,
flower and vegetable gardens can provide a lot
of pleasure well into autumn if you tend your
plants carefully.
In perennial beds, protect plants from
frost by cutting stems to the ground and
shoveling about an inch of compost right
over the tops. After removing withered
annual flowers or vegetable plants, guard
remaining healthy annuals with floating row
covers, blankets or plastic sheets. Remember
to insulate plants in the late afternoon, then
remove the covers in the morning once the
temperature warms. Often the first frost
will be followed by several weeks of mild
weather, so it’s worth the effort to help your
plants survive that first cold night.
Many vegetable plants, such as parsley,
kale, leeks and broccoli, and flowers such
as snapdragons and mums, tolerate cold
weather and won’t need protecting. They
will continue to produce food and flowers
until early winter.
Autumn also is an ideal time to plant trees
and shrubs because cool temperatures and
abundant rain allow roots to become well
established before winter. Many nurseries offer
deep discounts to dean out their stock, so bar
gains abound. Since sales can be tempting, be
sure to select the right plants for your location
and growing conditions.^
A Gardener’s Best Friend
These flexible, lightweight tubs are
washable, bendable, crushable! Haul
rocks, mix soils, transport root balls,
carry leaves, weeds and much more.
Comfortable handles too! FREE s&h!
Call 888-228-8804 for
Rugged Tub #35-592.
Use Code KMP7BBO4 to
get FREE s&h for Ameri
can Profile readers. Or
send check for $14.95 to
Dutch Gardens, AP Offers
-Tubs-8522, 128 Intervale
Rd., Burlington, VT 05401.
note: be sure to give us your
CHOICE OF COLORS.
www.americanprofile.com •
Orange
P| Green
■ Purple
Page 10